Hit Hard & Early

53
Hit hard and early! Gavin Giovannoni Barts and The London School of Medicine and Dentistry XVIIIth European Charcot Foundation Symposium Marbella , Spain 29 th Nov to 1 st Dec 2012

description

Background to why early aggressive treatment is an important emerging treatment strategy!

Transcript of Hit Hard & Early

Page 1: Hit Hard & Early

Hit hard and early!

Gavin Giovannoni

Barts and The London School of Medicine and Dentistry XVIIIth European Charcot Foundation Symposium

Marbella , Spain 29th Nov to 1st Dec 2012

Page 2: Hit Hard & Early

Disclosures

I have received personal compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from: Bayer-Schering Healthcare; Biogen-Idec; Canbex; Eisai; Elan; Fiveprime; Genzyme; Genentech; GSK; GW Pharma; Ironwood; Merck-Serono; Novartis; Pfizer; Roche; Sanofi-Aventis; Synthon BV; Teva; UCB Pharma; and Vertex Pharmaceuticals.

Page 3: Hit Hard & Early

Emerging concepts in MS

NEDD; no evidence of detectable disease

TTT; treat-to-target

Page 4: Hit Hard & Early

Emerging concepts in MS

NEDD; no evidence of detectable disease

TTT; treat-to-target

Page 5: Hit Hard & Early

How would you define a MS cure?

"To claim that someone has been cured of MS one would have to show that the person who had the disease had no disease activity for at least 15 years. The latter would be a composite of no MRI activity (new gadolinium-enhancing lesions, new T2 or enlarging T2 lesions and a lack of progressive whole brain atrophy) and no clinical activity (relapses or disease progression).“

GIOVANNONI; WWW.MS-RES.ORG: FRIDAY, 6 APRIL 2012.

Page 6: Hit Hard & Early

Coles et al. J Neurol. 2006 Jan;253(1):98-108..

Post-inflammatory neurodegeneration

Page 7: Hit Hard & Early

Hartung et al. Lancet 2002:360:2018-25.

Page 8: Hit Hard & Early

We don’t want to throw the baby out with the bathwater!

Page 9: Hit Hard & Early

Treat early

Natural course of disease

Later intervention

Later treatment

Treatment at diagnosis Intervention

at diagnosis

Time Disease Onset

Page 10: Hit Hard & Early

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN-1b trial

Goodin et al. Neurology 2012;78:1315-1322.

Page 11: Hit Hard & Early

Any Negative EDSS=6 SPMS Wheelchair

% R

isk R

ela

tive t

o L

ow

Exp

osu

re

Long-term follow-up 16 years

IFN-beta exposure 80% vs. 20%

Goodin et al. PLoS One. 2011;6(11):e22444. Epub 2011 Nov 30.

Establishing long-term efficacy: use of recursive partitioning and propensity score adjustment to estimate outcome in MS

Page 12: Hit Hard & Early

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon b-1b trial

Goodin et al. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):282-7.

Page 13: Hit Hard & Early

Association between use of interferon beta and progression of disability in MSers with relapsing-remitting multiple sclerosis

Tremlett et al. JAMA. 2012;308(3):247-256.

Page 14: Hit Hard & Early

Association between use of interferon beta and progression of disability in MSers with relapsing-remitting multiple sclerosis

Tremlett et al. JAMA. 2012;308(3):247-256.

Page 15: Hit Hard & Early

100 MSers

Who are the responders?

Page 16: Hit Hard & Early

~20% responders

~40% sub-optimal responders

~40% non-responders

Page 17: Hit Hard & Early

vs.

1

2

3

Clinical

MRI

NABs

Page 18: Hit Hard & Early

Relapses don’t count!

Page 19: Hit Hard & Early

Relapse on IFNβ Therapy Increases Risk of Sustained Disability Progression

Bosca et al. Mult Scler. 2008;14:636-639.

HR SE P Value 95% CI

No relapses (reference=1) 1

One relapse 3.41 1.47 0.005 1.46–7.98

Two or more relapses 4.37 1.74 0.000 1.90–9.57

HR of EDSS Increase in Patients with No Relapses, 1 Relapse, and 2 or More Relapses During the First 2 Years of IFN Treatment

0 20 40 60 80

0

0.25

0.50

0.75

Analysis Time (Months)

No Relapses One Relapse Two or More Relapses

1.00

EDSS

Pro

gres

sio

n

Surv

ival

Pro

bab

ility

HR=hazard ratio; SE=standard error

Page 20: Hit Hard & Early

Relapses and residual deficits

Lublin FD et al. Neurology. 2003;61:1528-1532.

Page 21: Hit Hard & Early

Predictors of long-term outcome in MSers treated with interferon beta-1a

Bermel et al. Ann Neuol 2012; In Press.

Page 22: Hit Hard & Early

Bermel et al. Ann Neuol 2012; In Press.

Predictors of long-term outcome in MSers treated with interferon beta-a

Page 23: Hit Hard & Early

Bermel et al. Ann Neuol 2012; In Press.

Predictors of long-term outcome in MSers treated with interferon beta-1a

Page 24: Hit Hard & Early

MRI activity doesn’t count!

Page 25: Hit Hard & Early

Bermel et al. Ann Neuol 2012; In Press.

Predictors of long-term outcome in MSers treated with interferon beta-1a

Page 26: Hit Hard & Early

MRI to monitor treatment response to IFNβ: a meta-analysis

Dobson et al. Submitted 2012.

Study or Subgroup Odds Ratio

IV, Random, 95% CI

Kinkel 2008

Prosperini 2009

Total (95% CI) 9.86 (2.33, 41.70)

Study or Subgroup Odds Ratio

IV, Random, 95% CI

Kinkel 2008

Pozzilli 2005

Prosperini 2009

Sormani 2011

Total (95% CI) 2.69 (0.72, 10.04)

0.01 0.1 1 10 100 Disease Less Likely Disease More Likely

One New T2 Lesion

Favors Experimental Favors Control

100 10 1 0.1 0.01

Two or More New T2 Lesions

Page 27: Hit Hard & Early

Study or Subgroup Odds Ratio

IV, Random, 95% CI

Kinkel 2008

Rio 2008

Total (95% CI) 5.46 (2.48, 12.04)

MRI to monitor treatment response to IFNβ: a meta-analysis

Dobson et al. Submitted 2012.

Study or Subgroup Odds Ratio

IV, Random, 95% CI

Kinkel 2008

Pozzilli 2005

Tomassini 2006

Total (95% CI) 3.34 (1.36, 8.22)

0.01 0.1 1 10 100 Disease Less Likely Disease More Likely

One New Gd+ Lesion

0.01 0.1 1 10 100

Disease Less Likely Disease More Likely

Two or More New Gd+ Lesions

Page 28: Hit Hard & Early

Disease progression doesn’t count!

Page 29: Hit Hard & Early

Strongest predictor of disability progression on IFNβ therapy is progression itself

Disease activity during 2 years of treatment and prediction of disability progression* at 6 years

Group Sensitivity (%)

(CI) Specificity (%)

(CI)

A. An increase of at least one EDSS step confirmed at 6 months 85 (64–95) 93 (86–97)

B. Occurrence of any relapse 80 (58–92) 51 (41–61)

C. Occurrence of two or more relapses 45 (26–66) 81 (72–82)

D. A decrease in relapse rate less than 30% compared with 2 years before therapy

40 (22–61) 86 (77–91)

E. A decrease in relapse rate less than 50% compared with 2 years before therapy

40 (–61) 81 (72–88)

F. No decrease or identical relapse rate compared with 2 years before therapy

35 (18–57) 88 (79–93)

G. Definition A or B 90 (70–97) 48 (38–58)

H. Definition A or E 85 (64–95) 76 (66–83)

I. Definition A and B 75 (53–89) 97 (91–99)

J. Definition A and E 40 (22–61) 99 (94–99)

*EDSS score ≥6.0 or increase in at least 3 EDSS steps.

Río J et al. Ann Neurol. 2006;59:344-352.

Page 30: Hit Hard & Early

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon b-1b trial

Goodin et al. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):282-7.

Page 31: Hit Hard & Early

Curved Ball

Page 32: Hit Hard & Early

0 3 6 X

Survival analysis and disability progression

Page 33: Hit Hard & Early

0 3 6 X

Survival analysis and disability progression

Page 34: Hit Hard & Early

0 3 6 X

Survival analysis and disability progression

Page 35: Hit Hard & Early

X

X

X

X

X

X

3

Page 36: Hit Hard & Early

X

X

X

X

X

X

3

survival analysis

Page 37: Hit Hard & Early

X

X

X

X

X

X

3

survival analysis

median or mean EDSS

Page 38: Hit Hard & Early

Impact of early interferon beta-1b on disease evolution over 5-years in MSers with CIS

Freedman et al. WCTRIMS 2008.

survival analysis median or

mean EDSS

Page 39: Hit Hard & Early

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Coles et al. Lancet 2012: November 1, http://dx.doi.org/10.1016/

Page 40: Hit Hard & Early

survival analysis

median or mean EDSS

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Coles et al. Lancet 2012: November 1, http://dx.doi.org/10.1016/

Page 41: Hit Hard & Early

56.0

42.0

27.0

74.0

51.0

39.0

0

10

20

30

40

50

60

70

80

Clinical disease

activity-free

MRI

activity-free

MS disease

activity-free

CARE-MS I: Disease Activity Status – Proportion of Patients Free of MS Disease Activity

41.1

Pati

en

ts (

%)

Note: Clinical disease activity-free defined as absence of relapse or SAD; MRI activity-free defined as absence of new Gd-enhancing lesion or new or

enlarging T2 hyperintense lesion; MS disease activity-free defined as absence of clinical disease activity or MRI activity.

Giovannoni et al. ENS 2012.

p<0.0001

p=0.0388

p=0.0064

SC IFNB-1a

Alem 12 mg

Page 42: Hit Hard & Early

“Every clinical trial is an experiment. In fact every time you treat a patient you should view it as an experiment and use it as an opportunity to learn something about the disease!”

Page 43: Hit Hard & Early

survival analysis

What is your treatment philosophy? maintenance-escalation vs. induction

Page 44: Hit Hard & Early

survival analysis

“hit hard and early ”

What is your treatment philosophy? maintenance-escalation vs. induction

Page 45: Hit Hard & Early

survival analysis

“hit hard and early ”

MS is an autoimmune disease hypothesis

15-20 year experiment

What is your treatment philosophy? maintenance-escalation vs. induction

Page 46: Hit Hard & Early

Who should decide?

Page 47: Hit Hard & Early

WWW.MS-RES.ORG

Page 48: Hit Hard & Early

WWW.MS-RES.ORG

Page 49: Hit Hard & Early

WWW.MS-RES.ORG

Page 50: Hit Hard & Early
Page 51: Hit Hard & Early

Are you prepared to walk where others fear to tread?

Page 52: Hit Hard & Early

Conclusions • NEDD, TTT and DAF are entering the neurology lexicon

• We need an acceptable working definition of an MS cure • DAF x 15 years?

• Should the definition be disease-stage specific?

• How do we deal with maintenance and induction therapies? • Maintenance - absence of DAF status indicates non-response

• Induction – absence of DAF status indicates a time to retreat

• Improve risk mitigation tool

• Who should make the decision re early aggressive treatment? • Regulators

• Payers

• Neurologists

• MSers

• Is it fair to make MSers wait 20 years for the outcome of an experiment? • Alemtuzumab extension study

• What do we do about post-inflammatory neurodegeneration? • We need better outcomes, e.g. regional brain atrophy and CSF neurofilament levels

• Neuroprotective treatments

Page 53: Hit Hard & Early

Conclusions • NEDD, TTT and DAF are entering the neurology lexicon

• We need an acceptable working definition of an MS cure • DAF x 15 years?

• Should the definition be disease-stage specific?

• How do we deal with maintenance and induction therapies? • Maintenance - absence of DAF status indicates non-response

• Induction – absence of DAF status indicates a time to retreat

• Improve risk mitigation tool

• Who should make the decision re early aggressive treatment? • Regulators

• Payers

• Neurologists

• MSers

• Is it fair to make MSers wait 20 years for the outcome of an experiment? • Alemtuzumab extension study

• What do we do about post-inflammatory neurodegeneration? • We need better outcomes, e.g. regional brain atrophy and CSF neurofilament levels

• Neuroprotective treatments

? ?